Methodology

Collection and Data Analysis Methodology

The Working Group has employed a standardized methodology since 2004 to generate comprehensive statistics on investment in HIV prevention research and development, including disaggregated trends. These methods were employed to generate the estimates of funding for R&D presented in this report. Categories used to describe different R&D activities were derived from those developed by the US NIH and are shown on the website. A set of questions on COVID-19 were specially added in response to ongoing impacts of the pandemic in 2020 and 2021.

Data Collection Categories

Preventive HIV vaccines
Microbicides
Multipurpose prevention technologies
Pre-exposure Prophylaxis (PrEP)
Treatment as prevention (TasP)
Male circumcision
Female condom
Prevention of mother-to-child transmission (PMTCT)
HIV cure
Therapeutic AIDS vaccines

Resource Tracking for HIV Prevention R&D Working Group

This analysis is made possible by the generous support of several donors, including the Bill and Melinda Gates Foundation, and the American people through the US President’s Emergency Plan for AIDS Relief (PEPFAR) and the US Agency for International Development (USAID) as part of the Coalition to Accelerate and Support Prevention Research (CASPR) project. The contents are the responsibility of AVAC and do not necessarily reflect the views of PEPFAR, USAID or the United States Government. AVAC does not accept funding from the pharmaceutical industry.

The Resource Tracking for HIV Prevention R&D Working Group (RTWG) is led by AVAC in partnership with the International AIDS Vaccine Initiative and UNAIDS

© 2023 HIV Resource Tracking